And let's keep in mind that HemaXellerate isn't some foreign compound introduced into the patient; it is custom developed from the endothelial cells of that exact patient's own fatty (adipose) tissue. While I'm certainly no expert, this process sounds safer than injecting some stock drug into the patient.
Bottom line - I'm fairly confident that the safety study is highly reproducible to what was seen already. Hoping to see an announcement of the safety study timeline and/or progress within the next couple weeks/months.
News 
Market Data 
Discover 
AI
